CA
NZ
UK
AU
IND
US
…
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications in the United States. The company develops antisense and small molecule injectable drugs for the treatment of cancer. It is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer, melanoma, and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. In addition, the company develops CA4P for the treatment of advanced metastatic melanoma; AL-101, an intranasal drug and delivery system for intra-nasal apomorphine for the treatment of parkinson's disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of support technologies, as well as nanoparticle products for the treatment of various cancers. The company is based in Agoura Hills, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 360.57M | -4.78M | -8.21M | 4.68M | -10.52M |
| Minority interest | 0.25M | 0.26M | 0.30M | 0.42M | 1.13M |
| Net income | 249.28M | -4.52M | -7.90M | 5.09M | -9.39M |
| Selling general administrative | 3.18M | 0.38M | 0.57M | 4.85M | 5.47M |
| Reconciled depreciation | - | - | 0.00M | 0.01M | 0.06M |
| Ebit | - | - | - | -5.61M | -9.13M |
| Ebitda | - | - | - | 7.66M | -8.45M |
| Operating income | -3.19M | -0.38M | -0.56M | -5.61M | -9.13M |
| Interest expense | 0.89M | 0.86M | 1.04M | 2.97M | 2.00M |
| Tax provision | 111.55M | 0.00M | - | - | - |
| Net interest income | -0.89M | -0.86M | -1.04M | -2.97M | -2.00M |
| Total revenue | 0.00M | 0.00M | 0.07M | 0.00M | 0.00M |
| Total operating expenses | 3.19M | 0.38M | 0.63M | 5.61M | 9.13M |
| Total other income expense net | 364.65M | -3.55M | -6.60M | 13.26M | 0.61M |
| Net income from continuing ops | 249.02M | -4.78M | -8.21M | 4.68M | -10.52M |
| Net income applicable to common shares | - | - | - | 5.09M | -9.39M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 393.09M | 26.68M | 30.01M | 36.12M | 23.61M |
| Intangible assets | 1.10M | 1.10M | 1.10M | 1.10M | 1.92M |
| Other current assets | 1.04M | 0.01M | 0.06M | 0.02M | 0.02M |
| Total liab | 131.36M | 19.20M | 18.40M | 16.92M | 15.45M |
| Total stockholder equity | 262.76M | 8.25M | 12.13M | 19.41M | 7.96M |
| Deferred long term liab | - | - | - | 1.10M | 1.10M |
| Other current liab | 2.98M | 3.33M | 3.05M | 2.82M | 2.97M |
| Common stock | - | - | - | 3.92M | 3.75M |
| Capital stock | 4.43M | 4.07M | 3.99M | 3.92M | 3.75M |
| Retained earnings | 211.24M | -38.04M | -33.52M | -25.93M | -31.02M |
| Good will | 2.79M | 2.79M | 5.99M | 12.07M | 21.06M |
| Other assets | - | - | - | 1.10M | 1.10M |
| Cash | 0.09M | 0.09M | 0.17M | 0.24M | 0.57M |
| Total current liabilities | 18.14M | 19.20M | 16.50M | 16.92M | 15.45M |
| Net debt | 13.82M | 13.00M | 12.40M | 11.02M | 8.42M |
| Short long term debt | 12.25M | 13.09M | 10.68M | 11.26M | 8.99M |
| Total current assets | 1.20M | 0.13M | 0.27M | 0.30M | 0.63M |
| Long term investments | 388.00M | 22.65M | 22.65M | 22.64M | - |
| Net tangible assets | - | - | - | 7.34M | -13.93M |
| Net receivables | 0.05M | 0.02M | 0.02M | 0.02M | 0.02M |
| Long term debt | 1.66M | - | 1.90M | - | - |
| Accounts payable | 1.64M | 1.69M | 1.66M | 1.74M | 1.93M |
| Non current assets total | 391.89M | 26.54M | 29.74M | 35.81M | 22.99M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Change to liabilities | - | - | - | 0.80M | 0.22M |
| Net borrowings | 1.39M | 0.66M | 1.41M | 0.97M | 2.56M |
| Total cash from financing activities | 1.39M | 0.66M | 1.25M | 1.13M | 4.53M |
| Change to operating activities | - | - | - | -0.00M | 0.08M |
| Net income | 249.28M | -4.52M | -7.90M | 5.09M | -9.39M |
| Change in cash | 0.00M | -0.08M | -0.07M | -0.33M | 0.09M |
| Begin period cash flow | 0.11M | 0.19M | 0.26M | 0.59M | 0.49M |
| End period cash flow | 0.11M | 0.11M | 0.19M | 0.26M | 0.59M |
| Total cash from operating activities | -1.38M | -0.74M | -1.32M | -1.45M | -4.43M |
| Issuance of capital stock | - | - | 0.00M | 0.16M | 1.97M |
| Depreciation | - | - | 0.00M | 0.01M | 0.06M |
| Sale purchase of stock | - | - | -0.12M | - | - |
| Change to netincome | - | - | - | -9.34M | 3.14M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.11M | 0.35M | -0.09M | 0.80M | 0.33M |
| Stock based compensation | 2.38M | 0.00M | 0.00M | 0.90M | 0.76M |
| Other non cash items | 1.26M | 0.21M | 0.68M | -14.72M | 3.37M |
| Free cash flow | -1.38M | -0.74M | -1.32M | -1.45M | -4.43M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| OTLC Oncotelic Therapeutics Inc |
-0.00 17.50% |
0.02 | 0.05 | 4.04 | 54.90 | 0.05 | 109.74 | 0.08 |
| NVO Novo Nordisk A/S |
-0.04 0.09% |
40.41 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-12.16 2.20% |
540.99 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
9.56 0.99% |
970.83 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications in the United States. The company develops antisense and small molecule injectable drugs for the treatment of cancer. It is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer, melanoma, and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. In addition, the company develops CA4P for the treatment of advanced metastatic melanoma; AL-101, an intranasal drug and delivery system for intra-nasal apomorphine for the treatment of parkinson's disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of support technologies, as well as nanoparticle products for the treatment of various cancers. The company is based in Agoura Hills, California.
| Name | Title | Year Born |
|---|---|---|
| Dr. Vuong Trieu Ph.D. | Chairman & CEO | 1963 |
| Mr. Amit Shah | Chief Financial Officer | 1967 |
| Dr. Chulho Park Ph.D. | Consultant | 1967 |
| Dr. Anthony E. Maida III, B.A., MA, MBA, Ph.D. | Chief Clinical Officer of Translational Medicine & Director | 1952 |
| Mr. Saranjit Saund | CBO & GM of AI Division | 1958 |
| Dr. Larn Hwang | Chief Scientific Officer | 1963 |
| Dr. Fatih M. Uckun M.D., Ph.D. | Chief Medical Officer | NA |
| Dr. Seymour Howard Fein M.D. | Chief Regulatory Officer | 1949 |
| Mr. Burcak Beser | CTO of AI Division | NA |
| Dr. Vuong Trieu Ph.D. | CEO, President & Chairman | 1963 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.10%
Communication Services
+0.21%
Consumer Cyclical
-0.19%
Consumer Defensive
-0.24%
Energy
-0.14%
Financial Services
-0.02%
Financials
+0.71%
Healthcare
+0.82%
Industrials
+0.42%
Real Estate
-0.07%
Technology
+0.67%
Utilities
-0.13%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...